A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream

American Journal of Clinical Dermatology

Volumn 7, Issue 4, 2006, Pages 223-230

  Torok, Helen M ^a  

^a Trillium Creek Dermatology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BLEACHING AGENT; CORTICOSTEROID; COSMETIC; ETRETIN; ETRETINATE; FLUOCINOLONE ACETONIDE; GLYCOLIC ACID; HYDROQUINONE; ISOTRETINOIN; METHOTREXATE; PHOTOSENSITIZING AGENT; RETINOIC ACID; RETINOID; SUNSCREEN; TRI LUMA;

ACNE; ANTIINFLAMMATORY ACTIVITY; APPLICATION SITE REACTION; CHLOASMA; CREAM; DESQUAMATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY SKIN; ERYTHEMA; FACE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERPIGMENTATION; INFLAMMATION; LONG TERM CARE; NECK; PERIORAL DERMATITIS; PRIORITY JOURNAL; PROTECTIVE CLOTHING; PRURITUS; RASH; REVIEW; ROSACEA; SHORT COURSE THERAPY; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN IRRITATION; TELANGIECTASIA;

ADMINISTRATION, CUTANEOUS; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; HYDROQUINONES; KERATOLYTIC AGENTS; MELANOSIS; TIME FACTORS; TRETINOIN;

EID: 33747187497     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607040-00003     Document Type: Review

References (25)

1. Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol 1995; 131 (12): 1453-7
2. Sanchez NP, Pathak MA, Sato S, et al. Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol 1981; 4 (6): 698-710
3. Kauh YC, Zachian TF. Melasma. Adv Exp Med Biol 1999; 455: 491-9
4. Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol 1986; 15 (4 Pt 2): 894-9
5. Menter A. Rationale for the use of topical corticosteroids in melasma. J Drugs Dermatol 2004; 3 (2): 169-74
6. American Academy of Dermatology. Dermatologists dis-'patch' dark side of melasma [online]. Available from URL: http://www.aad.org/public/News/ News Releases/Press+Release+Archives/Skin+Conditions/Melasma.htm [Accessed 2005 Dec 22]
7. Taylor SC. Epidemiology of skin diseases in people of color. Cutis 2003; 71 (4): 271-5
8. Balkrishnan R, McMichael AJ, Camacho FT, et al. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003; 149 (3): 572-7
9. Katsambas A, Antoniou C. Melasma: classification and treatment. J Eur Acad Dermatol Venereol 1995; 4: 217-23
10. Engasser PG, Maibach HI. Cosmetic and dermatology: bleaching creams. J Am Acad Dermatol 1981; 5 (2): 143-7
11. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients: a vehicle-controlled clinical trial. Arch Dermatol 1994; 130 (6): 727-33
12. Sanchez JL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol 1982; 21 (1): 55-8
13. Haddad AL, Matos LF, Brunstein F, et al. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol 2003; 42 (2): 153-6
14. Griffiths CE, Finkel LJ, Ditre CM, et al. Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol 1993; 129 (4): 415-21
15. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003; 72 (1): 67-72
16. Torok H, Taylor S, Baumann L, et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol 2005; 4 (5): 592-7
17. Torok HM, Jones T, Rich P, et al. Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. Cutis 2005; 75 (1): 57-62
18. Grimes P, Kelly AP, Torok H, et al. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis 2006; 77 (3): 177-84
19. Gano SE, Garcia RL. Topical tretinoin, hydroquinone, and betamethasone valerate in the therapy of melasma. Cutis 1979; 23 (2): 239-41
20. Kang WH, Chun SC, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol 1998; 25 (9): 587-96
21. Berardesca E, Maibach H. Ethnic skin: overview of structure and function. J Am Acad Dermatol 2003; 48 (6 Suppl.): S139-42
22. Balkrishnan R, Kelly AP, McMichael A, et al. Improved quality of life with effective treatment of facial melasma. J Drugs Dermatol 2004; 3 (4): 247-51
23. Giannotti B, Melli MC. Current approaches to the treatment of melasma. Clin Drug Invest 1995; 10 Suppl. 2: 57-64
24. Kligman LH, Schwartz E, Lesnik RH, et al. Topical tretinoin prevents corticosteroid-induced atrophy without lessening the anti-inflammatory effect. Curr Probl Dermatol 1993; 21: 79-88
25. McMichael AJ, Griffiths CE, Talwar HS, et al. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996; 135 (1): 60-4